查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1935116

瘧疾藥物市場 - 全球產業規模、佔有率、趨勢、機會及預測（按藥物類型、藥物劑型、最終用戶、分銷管道、地區和競爭格局分類，2021-2031年）

Malaria Therapeutics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Drug Type, By Drug Formulation, By End User, By Distribution Channel, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 180 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

全球瘧疾治療市場預計將從 2025 年的 30.5 億美元成長到 2031 年的 67.2 億美元，年複合成長率為 14.07%。

該領域涵蓋多種專業藥物類別，例如以青蒿素為基礎的聯合療法和預防藥物，這些藥物旨在治療和預防瘧疾原蟲引起的感染疾病。市場成長的主要驅動力是全球持續存在的瘧疾負擔，這需要有效的治療通訊協定和化學預防策略；此外，國際衛生組織和捐助機構的大力支持也進一步推動了市場發展，這些機構致力於優先保障瘧疾流行地區的基本藥物供應。世界衛生組織（世衛組織）估計，到2024年，全球將有2.82億例瘧疾病例，凸顯了推動該產業發展的迫切公共衛生需求。

市場概覽
預測期 2027-2031
市場規模：2025年 30.5億美元
市場規模：2031年 67.2億美元
複合年成長率：2026-2031年 14.07%
成長最快的細分市場 奎寧
最大的市場 中東和非洲

然而，市場成長面臨一個重大障礙：抗瘧疾藥抗藥性的日益增強。尤其是在瘧疾高發生地區，已觀察到對青蒿素衍生物的部分抗藥性。這種生物適應性削弱了標準治療方法的療效，並迫使人們開發更複雜、更昂貴的治療方法。這不僅威脅到現有價格適中的治療方法的可行性，還造成了物流和財務方面的障礙，限制了下一代治療方案的廣泛商業性應用。

市場促進因素

推動全球瘧疾藥物市場發展的關鍵因素之一是國際衛生組織資金的大幅成長，這些資金有效地補貼了基本抗瘧疾藥和預防性治療的採購和分發。這筆資金注入對於彌合高昂的藥物研發成本與流行地區低購買力之間的差距至關重要，確保新型治療方法能夠惠及患者群體。例如，2024年1月，全球基金核准了92億美元的新津貼，用於加速2024年至2026年間對抗愛滋病、結核病和瘧疾的進程。這些投資直接促進了干涉策略的擴展，包括引入新一代醫療工具。因此，市場正迅速接受新的預防措施。 2024年12月，全球疫苗免疫聯盟（Gavi）報告稱，自瘧疾疫苗引入以來，已採購並向流行地區交付了超過1,200萬劑瘧疾疫苗。

同時，瘧疾高負擔地區瘧疾發病率的上升也推動了市場成長，而氣候變遷和蚊蟲棲息地的擴張加劇了這一趨勢。環境變化導致瘧疾感染季節延長，媒介傳播疾病的病媒生物的地理分佈範圍擴大，使得需要緊急治療的患者人數增加。這種持續的需求使得基於青蒿素的聯合療法和新興替代療法都保持著持續的商業性需求。近期流行病學數據凸顯了這種需求的迫切性。 2024年12月，世界衛生組織（世衛組織）指出，預計2023年全球瘧疾病例將比前一年增加約1,100萬例，這再次強調了持續供應和治療方法創新對於有效應對不斷成長的患者數量的重要性。

市場挑戰

抗瘧疾藥抗藥性是限制全球瘧疾治療市場成長的主要障礙。這種生物演化正在逐步降低標準療法的療效，尤其是基於青蒿素的聯合療法，迫使製藥開發商投入大量資金進行高風險的新化合物研發。以複雜的新一代分子取代現有的低成本學名藥，造成了巨大的經濟負擔，並延長了研發週期。因此，市場面臨生產力瓶頸，阻礙了經濟實惠的解決方案的擴充性，給投資者帶來不確定性，並延緩了對產生收入至關重要的重要新藥的商業性部署。

此外，抗藥性的蔓延需要嚴格且昂貴的監測機制來監測治療效果，這會耗盡流行國家的醫療預算。這種經濟壓力減少了對先進療法的投入，並限制了更新、更昂貴藥物的市場滲透率。近期抗藥性菌株傳播的數據表明，這個問題十分嚴重。據世界衛生組織（世衛組織）稱，到2024年，非洲區域至少有8個國家已確認或疑似對青蒿素衍生物的部分抗藥性。這一趨勢不僅威脅臨床療效，也造成了動盪的商業環境，迫使製造商不斷調整以適應現有產品系列生命週期的縮短。

市場趨勢

為規避標準青蒿素類藥物普遍存在的抗藥性問題，新型非青蒿素類藥物的引入是一項重要的發展趨勢。藥物研發人員正優先研發具有不同作用機制的化合物，以確保對不斷進化的寄生蟲株具有持續的療效。這種轉變體現在新一代聯合治療的研發進展中，例如加那普拉西多-美芬特林，這類療法旨在消除感染並阻斷傳播，而無需考慮青蒿素的敏感性。據諾華公司稱，一項於2025年11月開展的針對這種新型非青蒿素候選藥物的3期臨床試驗，在治療非複雜性瘧疾方面，經PCR校正的有效率達到了97.4%，達到了其主要終點，即療效不劣於目前的標準療法。

同時，兒童分散劑市場正在顯著擴張，旨在提高兒童（最脆弱的患者群體）的治療依從性和療效。製造商正逐步放棄需要壓碎的成人片劑，轉而擴大可溶性、偏好製劑的生產規模，以確保兒童用藥劑量準確。這種對兒童給藥系統的關注，促使全球衛生夥伴關係支持大規模採購，以彌合瘧疾流行國家的藥物取得缺口。根據《瘧疾藥物與獸藥》（MMV）報告顯示，截至2025年4月，兒童治療藥物Coartem分散片的全球累積分發量已達到5億劑，這凸顯了該行業為降低五歲以下兒童死亡率而擴大生產規模的努力。

目錄

第1章概述

第2章調查方法

第3章執行摘要

第4章：客戶評價

第5章 全球瘧疾治療市場展望

  • 市場規模及預測
    • 按金額
  • 市佔率及預測
    • 依藥物類型（青蒿素類聯合療法（ACT）、奎寧、Chloroquine、其他）
    • 依藥物劑型（錠劑、膠囊、注射劑等）
    • 依最終使用者（成人、兒童、孕婦、其他）分類
    • 按分銷管道（零售藥局、醫院、網路藥局）
    • 按地區
    • 按公司（2025 年）
  • 市場地圖

第6章：北美瘧疾藥物市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國家分析
    • 美國
    • 加拿大
    • 墨西哥

7. 歐洲瘧疾藥物市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國家分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

8. 亞太地區瘧疾藥物市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國家分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

第9章：中東和非洲瘧疾治療市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東和非洲：國家分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

第10章：南美洲瘧疾藥物市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國家分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章 市場動態

  • 促進要素
  • 任務

第12章 市場趨勢與發展

  • 併購
  • 產品發布
  • 最新進展

第13章：全球瘧疾藥物市場：SWOT分析

第14章：波特五力分析

  • 產業競爭
  • 新進入者的可能性
  • 供應商電力
  • 顧客權力
  • 替代品的威脅

第15章 競爭格局

  • Novartis AG
  • Sanofi SA
  • Pfizer Inc
  • GlaxoSmithKline Plc
  • Merck & Co Inc
  • F. Hoffmann-La Roche AG
  • Cipla Limited
  • Ajanta Pharma Limited

第16章 策略建議

第17章：關於研究公司及免責聲明

簡介目錄
Product Code: 15002

The Global Malaria Therapeutics Market is projected to expand from a valuation of USD 3.05 Billion in 2025 to USD 6.72 Billion by 2031, reflecting a compound annual growth rate of 14.07%. This sector encompasses a specialized category of pharmaceutical agents, such as artemisinin-based combination therapies and prophylactic drugs, developed to treat and prevent infections caused by Plasmodium parasites. Market momentum is primarily sustained by the persistent global disease burden, which necessitates effective treatment protocols and chemoprevention strategies, further bolstered by strong backing from international health organizations and donor agencies focused on prioritizing access to essential medicines in endemic areas. Highlighting the urgent public health needs driving this industry, the World Health Organization estimated there were 282 million global malaria cases in 2024.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 3.05 Billion
Market Size 2031USD 6.72 Billion
CAGR 2026-203114.07%
Fastest Growing SegmentQuinine
Largest MarketMiddle East & Africa

Conversely, market growth faces a substantial obstacle in the form of increasing antimalarial drug resistance, specifically partial resistance to artemisinin derivatives observed in high-burden territories. This biological adaptation undermines the effectiveness of standard-of-care regimens, requiring the creation of more intricate and expensive alternative treatments. As a result, the viability of existing affordable therapies is jeopardized, establishing logistical and financial barriers that limit the widespread commercial adoption of next-generation therapeutic solutions.

Market Driver

A primary factor accelerating the Global Malaria Therapeutics Market is the significant increase in funding from international health bodies, which effectively subsidizes the procurement and distribution of essential antimalarials and preventative treatments. This capital infusion is vital for bridging the gap between high drug development costs and the low purchasing power of endemic regions, ensuring that novel therapies reach patient populations. For example, The Global Fund approved US$9.2 billion in new grants in January 2024 to speed up the battle against HIV, tuberculosis, and malaria for the 2024-2026 period. Such investments directly facilitate the scaling of intervention strategies, including the deployment of next-generation medical tools. Consequently, the market is witnessing a rapid uptake of new preventive measures; Gavi, the Vaccine Alliance, reported in December 2024 that over 12 million malaria vaccine doses had been procured and shipped to endemic countries since the rollout began.

Concurrently, the market is expanding due to the rising incidence of malaria in high-burden regions, a trend exacerbated by climate change and widening mosquito habitats. Environmental shifts are prolonging transmission seasons and expanding the geographical range of vectors, thereby raising the volume of patients requiring immediate therapeutic intervention. This persistent demand generates a sustained commercial requirement for both artemisinin-based combination therapies and emerging alternative drugs. The urgency of this demand is highlighted by recent epidemiological data; the World Health Organization noted in December 2024 that global malaria cases rose by approximately 11 million in 2023 compared to the prior year, reinforcing the critical need for continuous supply and innovation in therapeutic regimens to manage the growing patient load effectively.

Market Challenge

Antimalarial drug resistance constitutes a major hurdle significantly restricting the growth of the global malaria therapeutics market. This biological evolution renders standard-of-care treatments, specifically artemisinin-based combination therapies, increasingly ineffective, compelling pharmaceutical developers to redirect significant capital toward the high-risk discovery of novel compounds. The necessity to replace established, low-cost generics with complex next-generation molecules creates severe financial strain and extends research timelines. Consequently, the market encounters a productivity bottleneck where the scalability of affordable solutions is compromised, generating uncertainty for investors and delaying the commercial rollout of essential new medicines that are vital for revenue generation.

Furthermore, the proliferation of resistance necessitates rigorous and expensive surveillance mechanisms to monitor therapeutic efficacy, thereby draining healthcare budgets in endemic nations. This economic pressure reduces the available funds for purchasing advanced therapeutics, limiting the market penetration of newer, higher-priced drugs. The magnitude of this issue is evident in recent data regarding the spread of resistant strains; according to the World Health Organization, in 2024, partial resistance to artemisinin derivatives was confirmed or suspected in at least eight countries within the African region. This trend not only threatens clinical outcomes but also creates a volatile commercial environment where manufacturers must constantly adapt to the diminishing lifespan of their existing product portfolios.

Market Trends

The introduction of novel non-artemisinin drug classes constitutes a critical trend aimed at circumventing the widespread issue of partial resistance to standard artemisinin-based therapies. Pharmaceutical developers are prioritizing compounds with alternative mechanisms of action to ensure continued therapeutic efficacy against evolving parasite strains. This shift is exemplified by the advancement of next-generation combinations such as ganaplacide-lumefantrine, which are designed to clear infections independent of artemisinin susceptibility and block transmission. According to Novartis, in November 2025, the Phase 3 clinical trial for this novel non-artemisinin candidate achieved a PCR-corrected efficacy of 97.4% in treating uncomplicated malaria, meeting the primary endpoint of non-inferiority to current standards.

Simultaneously, the market is experiencing a significant expansion of pediatric-specific dispersible formulations intended to improve treatment adherence and outcomes among the most vulnerable patient demographic. Manufacturers are increasingly moving away from adult tablets that require crushing, instead scaling the production of soluble, palatable options that ensure accurate dosing for children. This focus on child-friendly delivery systems has led to massive procurement volumes supported by global health partnerships to bridge the access gap in endemic countries. According to Medicines for Malaria Venture, in April 2025, the cumulative global distribution of the pediatric treatment Coartem Dispersible reached a landmark 500 million courses, underscoring the industrial scale-up dedicated to reducing mortality in children under five.

Key Market Players

  • Novartis AG
  • Sanofi S.A
  • Pfizer Inc
  • GlaxoSmithKline Plc
  • Merck & Co Inc
  • F. Hoffmann-La Roche AG
  • Cipla Limited
  • Ajanta Pharma Limited

Report Scope

In this report, the Global Malaria Therapeutics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Malaria Therapeutics Market, By Drug Type

  • Artemisinin-based combination therapy (ACT)
  • Quinine
  • Chloroquine
  • Others

Malaria Therapeutics Market, By Drug Formulation

  • Tablets
  • Capsules
  • Injectables
  • Others

Malaria Therapeutics Market, By End User

  • Adults
  • Children
  • Pregnant Women
  • Others

Malaria Therapeutics Market, By Distribution Channel

  • Retail pharmacies
  • Hospitals
  • Online pharmacies

Malaria Therapeutics Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Malaria Therapeutics Market.

Available Customizations:

Global Malaria Therapeutics Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Malaria Therapeutics Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Drug Type (Artemisinin-based combination therapy (ACT), Quinine, Chloroquine, Others)
    • 5.2.2. By Drug Formulation (Tablets, Capsules, Injectables, Others)
    • 5.2.3. By End User (Adults, Children, Pregnant Women, Others)
    • 5.2.4. By Distribution Channel (Retail pharmacies, Hospitals, Online pharmacies)
    • 5.2.5. By Region
    • 5.2.6. By Company (2025)
  • 5.3. Market Map

6. North America Malaria Therapeutics Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Drug Type
    • 6.2.2. By Drug Formulation
    • 6.2.3. By End User
    • 6.2.4. By Distribution Channel
    • 6.2.5. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Malaria Therapeutics Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Drug Type
        • 6.3.1.2.2. By Drug Formulation
        • 6.3.1.2.3. By End User
        • 6.3.1.2.4. By Distribution Channel
    • 6.3.2. Canada Malaria Therapeutics Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Drug Type
        • 6.3.2.2.2. By Drug Formulation
        • 6.3.2.2.3. By End User
        • 6.3.2.2.4. By Distribution Channel
    • 6.3.3. Mexico Malaria Therapeutics Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Drug Type
        • 6.3.3.2.2. By Drug Formulation
        • 6.3.3.2.3. By End User
        • 6.3.3.2.4. By Distribution Channel

7. Europe Malaria Therapeutics Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Drug Type
    • 7.2.2. By Drug Formulation
    • 7.2.3. By End User
    • 7.2.4. By Distribution Channel
    • 7.2.5. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Malaria Therapeutics Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Drug Type
        • 7.3.1.2.2. By Drug Formulation
        • 7.3.1.2.3. By End User
        • 7.3.1.2.4. By Distribution Channel
    • 7.3.2. France Malaria Therapeutics Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Drug Type
        • 7.3.2.2.2. By Drug Formulation
        • 7.3.2.2.3. By End User
        • 7.3.2.2.4. By Distribution Channel
    • 7.3.3. United Kingdom Malaria Therapeutics Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Drug Type
        • 7.3.3.2.2. By Drug Formulation
        • 7.3.3.2.3. By End User
        • 7.3.3.2.4. By Distribution Channel
    • 7.3.4. Italy Malaria Therapeutics Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Drug Type
        • 7.3.4.2.2. By Drug Formulation
        • 7.3.4.2.3. By End User
        • 7.3.4.2.4. By Distribution Channel
    • 7.3.5. Spain Malaria Therapeutics Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Drug Type
        • 7.3.5.2.2. By Drug Formulation
        • 7.3.5.2.3. By End User
        • 7.3.5.2.4. By Distribution Channel

8. Asia Pacific Malaria Therapeutics Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Drug Type
    • 8.2.2. By Drug Formulation
    • 8.2.3. By End User
    • 8.2.4. By Distribution Channel
    • 8.2.5. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Malaria Therapeutics Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Drug Type
        • 8.3.1.2.2. By Drug Formulation
        • 8.3.1.2.3. By End User
        • 8.3.1.2.4. By Distribution Channel
    • 8.3.2. India Malaria Therapeutics Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Drug Type
        • 8.3.2.2.2. By Drug Formulation
        • 8.3.2.2.3. By End User
        • 8.3.2.2.4. By Distribution Channel
    • 8.3.3. Japan Malaria Therapeutics Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Drug Type
        • 8.3.3.2.2. By Drug Formulation
        • 8.3.3.2.3. By End User
        • 8.3.3.2.4. By Distribution Channel
    • 8.3.4. South Korea Malaria Therapeutics Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Drug Type
        • 8.3.4.2.2. By Drug Formulation
        • 8.3.4.2.3. By End User
        • 8.3.4.2.4. By Distribution Channel
    • 8.3.5. Australia Malaria Therapeutics Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Drug Type
        • 8.3.5.2.2. By Drug Formulation
        • 8.3.5.2.3. By End User
        • 8.3.5.2.4. By Distribution Channel

9. Middle East & Africa Malaria Therapeutics Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Drug Type
    • 9.2.2. By Drug Formulation
    • 9.2.3. By End User
    • 9.2.4. By Distribution Channel
    • 9.2.5. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Malaria Therapeutics Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Drug Type
        • 9.3.1.2.2. By Drug Formulation
        • 9.3.1.2.3. By End User
        • 9.3.1.2.4. By Distribution Channel
    • 9.3.2. UAE Malaria Therapeutics Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Drug Type
        • 9.3.2.2.2. By Drug Formulation
        • 9.3.2.2.3. By End User
        • 9.3.2.2.4. By Distribution Channel
    • 9.3.3. South Africa Malaria Therapeutics Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Drug Type
        • 9.3.3.2.2. By Drug Formulation
        • 9.3.3.2.3. By End User
        • 9.3.3.2.4. By Distribution Channel

10. South America Malaria Therapeutics Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Drug Type
    • 10.2.2. By Drug Formulation
    • 10.2.3. By End User
    • 10.2.4. By Distribution Channel
    • 10.2.5. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Malaria Therapeutics Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Drug Type
        • 10.3.1.2.2. By Drug Formulation
        • 10.3.1.2.3. By End User
        • 10.3.1.2.4. By Distribution Channel
    • 10.3.2. Colombia Malaria Therapeutics Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Drug Type
        • 10.3.2.2.2. By Drug Formulation
        • 10.3.2.2.3. By End User
        • 10.3.2.2.4. By Distribution Channel
    • 10.3.3. Argentina Malaria Therapeutics Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Drug Type
        • 10.3.3.2.2. By Drug Formulation
        • 10.3.3.2.3. By End User
        • 10.3.3.2.4. By Distribution Channel

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Malaria Therapeutics Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Novartis AG
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Sanofi S.A
  • 15.3. Pfizer Inc
  • 15.4. GlaxoSmithKline Plc
  • 15.5. Merck & Co Inc
  • 15.6. F. Hoffmann-La Roche AG
  • 15.7. Cipla Limited
  • 15.8. Ajanta Pharma Limited

16. Strategic Recommendations

17. About Us & Disclaimer